{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-092957","form_type":"8-K","ticker":"IMRX","cik":"0001790340","company_name":"Immuneering Corp","filed_at":"2025-09-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.006092+00:00","generated_at":"2026-05-17T05:48:18.683301+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Immuneering signs $25M Sanofi placement contingent on public offering; Phase 2a pancreatic data shows 86% OS","bullets":["Sanofi subsidiary Aventis agrees to purchase $25M in stock at public offering price; closing contingent on $75M+ public offering by Sept 26, 2025.","Updated Phase 2a atebimetinib + mGnP data in 1L pancreatic cancer (N=34): 86% OS at 9 mos (vs ~47% SOC), median PFS 9.6 mos, median OS not reached.","Safety profile: Grade ≥3 TEAEs in ≥10% were anemia (24%) and neutropenia (18%); no Grade 5 events.","Near-term milestones: regulatory feedback on Phase 3 plans in Q4 2025; potential Phase 3 start by end 2025 and first patient by mid-2026.","Leerink Partners and Oppenheimer & Co. act as joint bookrunners for the public offering and placement agents for private placement."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-092957","json":"https://secwatch.observer/filing/0001104659-25-092957.json","markdown":"https://secwatch.observer/filing/0001104659-25-092957.md","text":"https://secwatch.observer/filing/0001104659-25-092957.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1790340/000110465925092957/0001104659-25-092957-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1790340/000110465925092957/tm2526843d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:48:18.683301+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"69a7767b71e92e66fab1a01222642d6654ed6765","claim":"Immuneering Corp issued $25.0 million of shares of the Company's Class A common stock or, in certain circumstances, shares of the Company's non-voting Class B common stock of common stock to Aventis Inc. for The price per Share will be the price per share of Class A Common Stock to the public in the Public Offering as set forth on the cover of the definitive prospec.","evidence_excerpt":"On September 24, 2025, Immuneering Corporation (the \"Company\") entered into a securities purchase agreement (the \"Purchase Agreement\") with Aventis Inc. (the \"Investor\"), a wholly owned subsidiary of Sanofi, a French société anonyme, pursuant to which the Company, in a private placement transaction (the \"Private Placement\"), agreed to issue and sell to the Investor $25.0 million of shares (the \"Class A Shares\") of the Company's Class A common stock, par value $0.001 per share (\"Class A Common Stock\"), or in certain circumstances in lieu of Class A Shares, shares (the \"Class B Shares\" and, together with the Class A Shares, collectively, the \"Shares\") of the Company's non-voting Class B common stock, par value $0.001 per share (\"Class B Common Stock\"), subject to and contingent upon the closing of a firm commitment underwritten public offering of Class A Common Stock by the Company that results in gross proceeds to the Company of at least $75.0 million and the pricing of which is publicl","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1790340/000110465925092957/0001104659-25-092957-index.htm","confidence":0.95,"family_label":"Equity Issuances","details":[{"label":"Security","value":"common stock"},{"label":"Shares","value":"$25.0 million of shares of the Company's Class A common stock or, in certain circumstances, shares of the Company's non-voting Class B common stock"},{"label":"Purchaser","value":"Aventis Inc."},{"label":"Consideration","value":"The price per Share will be the price per share of Class A Common Stock to the public in the Public Offering as set forth on the cover of the definitive prospec"}],"fact_type":"equity_issuance"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}